Asset profile
Sodium Oxybate
Small molecule
Evidence outlook
Approved: Narcolepsy
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Also in development:Idiopathic Hypersomnia · Phase 3
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Competitive landscape
4 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 4 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Sodium Oxybate: this drug | Approved | Small molecule | GABA-B receptor | ||
| Pitolisant (Wakix) | Approved | Small molecule | Histamine H3 receptor (antagonist / inverse agonist) | ||
| Solriamfetol (Sunosi) | Approved | Small molecule | Dopamine/norepinephrine transporter | ||
| ALKS 2680 | Phase 3 | Small molecule | — | ||
| Reboxetine | Phase 3 | Small molecule | norepinephrine transporter |
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(8 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (7)
January 2027 (1)
What to watch
June 2027 (1)
September 2027 (3)
What to watch
What to watch
What to watch
October 2027 (1)
What to watch
December 2027 (1)
2028 (1)
December 2028 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.